newsfilter
← Latest News
Business Wire·

Sesen Bio Reports First Quarter 2022 Financial Results and Business Update

Strong balance sheet of $170 million in cash and cash equivalents as of March 31, 2022, expected to fund current operating plan into the fourth quarter of 2024 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein